STAT+: Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots
Good morning and congrats if you caught the “ring of fire” some of us in…
Author: STAT
Opinion: Lessons about marijuana edibles from youth vaping
When it comes to children’s health, parents — and public activism — can make a…
Opinion: The future of pandemic preparedness: agile coordination around clinical trials
The SARS-CoV-2 virus presented the world with a host of clinical challenges, not least its…
Watch: SPACs are all the rage, but what are they? STAT explains
Wall Street’s hottest new trend is a 1980s retread: Private firms are merging with so-called…
More transmissible, wilier variant makes Covid-19 vaccinations even more crucial, experts say
It’s getting even riskier to remain unvaccinated. The United States, as a whole, is still…
As more kids go down the ‘deep, dark tunnel’ of long Covid, doctors still can’t predict who is at risk
At 14 years old, Kate Dardis knows what pain feels like and how to work…
A safer, low dose of laughing gas may be enough to help some patients with major depression, study finds
Laughing gas may be most associated with its use in dentistry, but in recent years,…
STAT+: WTO members agree to step up talks about Covid-19 intellectual property proposals
In what is being described as a “major breakthrough,” a World Trade Organization council agreed…
.jpg)
STAT+: ‘Some very noble, some less than noble’: The growing health data marketplace sparks concern over patient privacy
The electronic health record has ushered in a golden era of precision medicine. It’s also…
Virtual Event: The ASCO Recap, Live!
After the biggest meeting in cancer research, sit down with cancer’s biggest decision-maker: the director…
STAT+: Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
Opinion: Listen: Healing the healers: An advocate and a psychiatrist on clinicians’ mental health and burnout
This week on the “First Opinion Podcast,” I’m joined by Corey Feist and Wendy Dean…
STAT wants to know your pick for a great summer read or listen
STAT is putting together a list of books and podcasts that deal with health, medicine,…
Opinion: If pediatrics board can’t lead with its maternity leave policy, it should at least follow
When my daughter started to reveal just how comfortable she was in utero, and wasn’t…
More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows
WASHINGTON — Seventy-two senators and 302 members of the House of Representatives cashed a check…
Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds
WASHINGTON — State lawmakers in Oregon have tried to lower high drug prices from nearly…
STAT+: Regeneron shareholders urged to boot board member over executive pay practices
Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove the board…
Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval
Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday,…
STAT+: Biogen, FDA at odds over timing of crucial confirmatory trial of Alzheimer’s drug
Biogen and the Food and Drug Administration are at odds over the timing of a…
Opinion: Bad medicine: aducanumab is a lackluster drug with a high price tag
Controversy has swirled around aducanumab, an experimental drug developed by Biogen, long before the FDA…
STAT+: Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug
Amid a firestorm of controversy around its decision to charge $56,000 a year for an…
STAT+: STAT+ Conversations: Discussing Biogen’s Alzheimer’s drug
Editors note: A livestream of the conversation will be embedded below at 1:00pm ET. Every…
STAT+: Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare
Top of the morning to you. And a steamy one, it is. In fact, there…
Opinion: Scientific publishing’s new weapon for the next crisis: the rapid correction
Some observers have hailed the response to Covid-19 as a triumph for science. A hesitant…
CPR coaching over the phone can save lives. A new model makes it easier for people who speak limited English
New research finds that a Los Angeles program to coach 911 callers through providing CPR…
STAT+: Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate
WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly…
.jpg)
Elation, pride, and a slew of questions: Clinical trial participants reflect on their own complicated reactions to Aduhelm approval
For the roughly 3,500 people who volunteered as clinical trial participants for the Alzheimer’s therapy…
STAT+: Biogen’s big day is a Wall Street windfall for biotechs in Alzheimer’s
As Biogen soared Monday on the surprise Food and Drug Administration approval of its hotly…
Apple announces new features to share health data with doctors, track trends over time
Apple is making it easier than ever for users to make the most of the…
An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug
As if the saga of aducanumab needed another twist, the Food and Drug Administration tossed…
STAT+: ‘The price is bewildering’:The price of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks
The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen…
STAT+: One Medical eyes the full lifespan with acquisition of Medicare-focused Iora Health
One Medical announced its plan on Monday to acquire Iora Health, expanding its primary care…
STAT+: Why Biogen may be sitting on the most lucrative product in pharmaceutical history
Biogen’s quest to win approval for a new Alzheimer’s disease treatment once seemed futile. Now…
STAT+: By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk
In order to approve a new Alzheimer’s treatment, the Food and Drug Administration is rewriting…
FAQs: What you need to know about the Alzheimer’s drug Aduhelm
The Food and Drug Administration on Monday approved Biogen’s new Alzheimer’s drug, a decision with…
Opinion: FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs
The Food and Drug Administration yanked the fight against Alzheimer’s out of the mire with…
FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
The Food and Drug Administration on Monday approved the first new treatment for Alzheimer’s disease…
STAT+: Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Onduo’s new exec on Google’s data skills, real-world evidence, and moving the needle on outcomes
After leading the charge at Duke University to free health care data from its silos,…
Opinion: With Covid-19, as with HIV, science and partnerships with communities lead the way
Like so many of her generation, Josephine Nabukenya wasn’t aware of her HIV status during…
Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding
“Mount up! Let’s hear more about this unicorn.” So begins every episode of a new…
STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells…
Heart reaction probed as possible rare Covid-19 vaccine link in teens
Health authorities are trying to determine whether heart inflammation that can occur along with many…
STAT+: EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’
Amid intense debate over equitable access to Covid-19 vaccines, the European Union is offering a…
STAT+: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?
Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells…
STAT+: Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Carbon Health dives into digital diabetes care with virtual clinic acquisition
As health care providers large and small prepare for a transition from virtual to in-person…
Opinion: 40 years of AIDS should have taught us epidemiologic humility
Forty years later, I can still recall my visceral reaction to reading an article in…
A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care
Come Monday, we should learn whether the Food and Drug Administration will approve the first…
STAT+: Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’
Martin Shkreli’s drug company has a lot of problems. Revenue was cut in half last…